| Objective: To investigate the influence of portal vein chemotherapy with 5-FU for colorectal cancer on postoperative hematogenous micrometastasis of tumor cells and immune function.Methods: Peripheral blood samples were collected from 27 patients with portal vein chemotherapy after curative resection of colorectal cancer, and other 23 patients without portal vein chemotherapy as control. CK20mRNA was detected by nested reverse transcriptase polymerase chain reaction(RT-PCR), cellular immune indicators was detected by Flow Cytometry and immunoglobulin was detected by Nephelometry on the occasion of 1 day before the operation, immediately after the operation, the 8th day and 20th day after the operation.Results: 1. The positive expression rate of CK20mRNA in postoperative peripheral blood samples for experimental group and control group were respectively 77.8% and 73.9% which were significantly higher than those 40.7% and 39.1% in preoperative blood samples (P<0.05).2. The positive expression rate of CK20mRNA between postoperative blood samples of portal vein and peripheral vein were respectively 85.2% and 77.8% in the experimental group. The positive expression rate of CK20mRNA between postoperative blood samples of portal vein and peripheral vein were respectively 78.3% and 73.9% in the control group. The positive expression rate of CK20mRNA between postoperative blood samples of portal vein and peripheral vein showed no significant difference in both groups (P>0.05).3. With portal vein chemotherapy, the positive expression rates of CK20mRNA on the 8th, 20th day after the operation were respectively 37.0% and 33.3%. And respectively 69.6% and 78.3% for control group. The positive expression rates of the experimental group were significantly lower than those of the control group (P<0.05). 4. The levels of CD3+, CD4+, CD4+/CD8+, NK cell and IgG, IgM in the blood samples of colorectal cancer patients were significantly lower than those in the healthy control group (P<0.05), however the levels of CD8+ cells and IgA were not, and there's no significant difference between colorectal cancer patients and healthy control (P>0.05).5.The levels of CD3+, CD4+, CD4+/CD8+, NK cell and IgG in the blood samples of colorectal cancer patients on the occasion immediately after the operation were significantly lower than those in the preoperative blood samples (P<0.05), however there's no significant difference in the levels of CD8+ cells, IgA and IgM (P>0.05).6. With portal vein chemotherapy, the levels of CD3+, CD4+, CD4+/CD8+ , NK cells and IgM on the 8th day after operation were significantly lower than those in the control group (P<0.05), however the levels of CD8+ cells and IgG, IgA were not, and there's no significant difference between experimental and control group(P>0.05).7. All the immune indicators on the 20th day showed no significant difference compaired with the day before operation both in experimental and control group (P>0.05).Conclusions: 1 There have been tumor cells in the blood cycle of colorectal patients before distant organ metastasis happened.2 Operation on colorectal cancer patients may increase the risk of hematogenous tumor micrometastasis. Portal vein chemotherapy with 5-FU for colorectal cancer after resection may decrease the risk of hematogenous tumor micrometastasis.3 The immune functions of colorectal cancer patients were significantly lower than that of healthy ones, and the operation as a kind of trauma may further decrease the immune functions,especially the cellular immune functions. With 5-FU portal vein chemotherapy, the immune functions may be suppressed in a short-term way, but can be recovered on the 20th day after operation.
|
PDF Full Text Request